Glycoside Hydrolases

Name
Glycoside Hydrolases
Accession Number
DBCAT000166
Description

Not Available

Drugs
DrugDrug Description
Hyaluronidase (ovine)A purified form of sheep hyaluronidase enzyme used as an adjunct in subcutaneous rehydration therapy and to increase absorption of other drugs and radiopaque imaging agents.
ImigluceraseA form of recombinant human beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease.
AlgluceraseA form of recombinant beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease.
Agalsidase betaA recombinant human alpha-galactosidase indicated to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide.
Alglucosidase alfaAn acid alpha- glucosidase (GAA) derivative used as an enzyme replacement therapy for the treatment of Pompe disease in infants and pediatric patients caused by GAA deficiency.
ALTU-135Investigated for use/treatment in cystic fibrosis and pancreatic disorders.
SacrosidaseAn enzyme replacement therapy used for the treatment of congenital sucrase-isomaltase deficiency (CSID).
Taliglucerase alfaA hydrolytic lysosomal glucocerebroside specific enzyme, used for long term enzyme replacement therapy in patients with Type 1 Gaucher disease.
Pancrelipase amylaseA lipase used to treat pancreatic exocrine insufficiency.
AviscumineCy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).
LysozymeAn enzyme indicated in the treatment of gastrointestinal disorders in infants, as well as Herpes zoster and Herpes simplex.
TilactaseA beta-D-galactosidase use to treat lactose intolerance.
Hyaluronidase (human recombinant)An enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
HyaluronidaseAn enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
Valanafusp alfaValanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
Agalsidase alfaA recombinant human alpha-galactosidase indicated to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide.
Drugs & Drug Targets
DrugTargetType
Hyaluronidase (ovine)Transforming growth factor beta-1target
Hyaluronidase (ovine)Serum albumincarrier
Hyaluronidase (ovine)Hyaluronantarget
ImigluceraseGlucocerebrosidetarget
AlgluceraseGlucocerebrosidetarget
Agalsidase betaGlobotriaosylceramidetarget
Agalsidase betaCation-dependent mannose-6-phosphate receptortransporter
Alglucosidase alfaCation-dependent mannose-6-phosphate receptortarget
Alglucosidase alfaGlycogentarget
Taliglucerase alfaGlucocerebrosidetarget
Pancrelipase amylaseDietary starchtarget
TilactaseLactosetarget
Hyaluronidase (human recombinant)Hyaluronic acidtarget
Hyaluronidase (human recombinant)Transforming growth factor beta-1target
HyaluronidaseHyaluronic acidtarget
HyaluronidaseTransforming growth factor beta-1target
Agalsidase alfaCation-dependent mannose-6-phosphate receptortransporter
Agalsidase alfaGlobotriaosylceramidetarget